Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18456032 | 0.82 | KDM4E (0.53) | KDM4EPKMMAOAMAOBTDP1 | |
| SCHEMBL14105877 | 0.81 | MAOA (0.59) | KDM4EPKMMAOAMAOBTDP1 | |
| SCHEMBL18754495 | 0.81 | GPR3 (0.55) | ESR1ESR2GAAMAPTNPSR1 | |
| SCHEMBL27943843 | 0.80 | TDP1 (0.52) | KDM4EPKMMAOAMAOBTDP1 | |
| Ammonia Solution, Strong SCHEMBL28019425 | 0.79 | GPR3 (0.53) | ESR1ESR2GAAMAPTNPSR1 | |
| SCHEMBL20851768 | 0.79 | KDM4E (0.46) | KDM4EMAOATDP1GAAMAPT | |
| SCHEMBL5469806 | 0.79 | MAOA (0.56) | KDM4EPKMMAOAMAOBTDP1 | |
| SCHEMBL11576048 | 0.78 | KDM4E (0.51) | KDM4EMAOATDP1GAAMAPT | |
| SCHEMBL31504610 | 0.76 | L3MBTL1 (0.54) | KDM4EPKMTDP1MAPTNPSR1 | |
| SCHEMBL15978466 | 0.76 | ALDH1A1 (0.52) | KDM4EMAOAMAOBTDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912647-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERICAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-11 | — | — | EP | disclosed |
| CN-101277695-B | Quinoline derivatives as antibacterial agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-14 | — | — | CN | disclosed |
| US-8017606-B2 | Therapy for bacteria infections other than Mycibacterium infections; antibiotic resistance | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-13 | — | — | US | disclosed |
| US-20110124870-A1 | NOVEL MYCOBACTERIAL INHIBITORS | JANSSEN-CILAG (FR) | 2011-05-26 | — | — | US | disclosed |
| US-7902225-B2 | Mycobacterial inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | disclosed |
| CN-1909907-B | Quinoline derivatives and use thereof for preparing mycobacterial inhibitors | JANSSEN PHARMACEUTICA NV | 2010-06-23 | — | — | CN | disclosed |
| EP-1711181-B1 | QUINOLINE DERIVATIVES AND USE THEREOF AS MYCOBACTERIAL INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-30 | — | — | EP | disclosed |
| US-20080255116-A1 | Therapy for bacteria infections other than Mycibacterium infections; antibiotic resistance | JANSSEN PHARMACEUTICA N.V. | 2008-10-16 | — | — | US | disclosed |
| CN-101277695-A | Quinoline derivatives as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2008-10-01 | — | — | CN | disclosed |
| EP-1912647-A2 | QUINOLINE DERIVATIVES AS ANTIBACTERICAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-23 | — | — | EP | disclosed |
| US-20070093478-A1 | Novel mycobacterial inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | US | disclosed |
| WO-2007014940-A2 | QUINOLINE DERIVATIVES AS ANTIBACTERICAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-08 | — | — | WO | disclosed |
| CN-1909907-A | Quinoline derivatives and use thereof as mycobacterial inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-07 | — | — | CN | disclosed |
| EP-1711181-A1 | QUINOLINE DERIVATIVES AND USE THEREOF AS MYCOBACTERIAL INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005070430-A1 | QUINOLINE DERIVATIVES AND USE THEREOF AS MYCOBACTERIAL INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-04 | — | — | WO | disclosed |
| EP-0740689-A1 | SUBSTITUTED UNSYMMETRICAL CYANINE DYES WITH SELECTED PERMEABILITY | MOLECULAR PROBES INC (US) | 1996-11-06 | — | — | EP | disclosed |
| EP-0093521-B1 | QUINOLINE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-08-24 | — | — | EP | disclosed |
| US-4607039-A | 2-(AMINO-ALKYL-THIO OR -OXY) SUBSTITUTED | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-08-19 | — | — | US | disclosed |
| EP-0093521-A2 | Quinoline derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124870-A1 | NOVEL MYCOBACTERIAL INHIBITORS | NQO2, NAT1, HRH1 | KDM4E 4569/4885PKM 2699/4885MAOA 268/4885 |
| US-20070093478-A1 | Novel mycobacterial inhibitors | NQO2, NAT1, HRH1 | KDM4E 4559/4885PKM 3006/4885MAOA 235/4885 |
| US-20080255116-A1 | Therapy for bacteria infections other than Mycibacterium infections; antibiotic resistance | RER1, HRH4, HRH1 | KDM4E 3332/4885PKM 4033/4885MAOA 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.